Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership
Initiative Will Produce Biosimilars Of Lantus, Humalog And Novolog
Executive Summary
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
You may also be interested in...
Non-Profit Outpatient Player CivicaScript Brings Packaging Specialist Aboard
As it continues plans to roll out low-cost insulin biosimilar products, CivicaScript has augmented its existing product offering via a collaboration with specialty pharmacy SortPak.
Pressure Builds For Biosimilars To Follow Lilly’s Lead After Insulin Price Cap
Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.
New Insulin Manufacturer For Civica
Ypsomed AG will manufacture insulin dosing injector pens for non-profit Civica. Civica has also paired up with AmerisourceBergen for generics supply chain support across the US.